Regulatory Uncertainty And 340B Pressures Will Erode Oncology Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
18 May 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
US$36.00
6.9% overvalued intrinsic discount09 Aug
US$38.47
1Y
46.2%7D
2.9%